Implications of EV 302 How do We Sequence Treatment in the Future

Shilpa Gupta, MD

Shilpa Gupta, MD, presented “Implications of EV 302 How do We Sequence Treatment in the Future” at the 7th International Bladder Cancer Update on December 6, 2024, in Dallas, Texas.

How to cite: Gupta, Shilpa. “Implications of EV 302 How do We Sequence Treatment in the Future” December 2024. Accessed Apr 2026. https://grandroundsinurology.com/implications-of-ev-302-how-do-we-sequence-treatment-in-the-future/

Implications of EV 302 How do We Sequence Treatment in the Future – Summary

Shilpa Gupta, MD, explores the evolving treatment paradigm in metastatic urothelial carcinoma following the EV-302 trial.

In this 6-minute presentation, Dr. Gupta reviews past treatment paradigms, explaining that, before the EV-302 trial, cisplatin-eligible patients typically received cisplatin-based chemotherapy followed by immunotherapy upon progression.

The current treatment paradigm prioritizes EV plus pembrolizumab as the frontline standard, followed by platinum-based chemotherapy upon progression. Dr. Gupta stresses that future research must optimize treatment sequences and develop novel therapies for patients who progress on EV plus pembrolizumab. Comprehensive genomic and IHC testing is essential for guiding treatment decisions and ensuring patients receive targeted therapies.

About the 7th International Bladder Cancer Update:

The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.

For further educational activities from this conference, visit our collection page.

ABOUT THE AUTHOR

Shilpa Gupta, MD

Shilpa Gupta, MD, is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at the Cleveland Clinic in Cleveland, Ohio. Dr. Gupta’s research interests include novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer.

About The Author

Shilpa Gupta, MD

Shilpa Gupta, MD, is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at the Cleveland Clinic in Cleveland, Ohio. Dr. Gupta’s research interests include novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta earned her medical degree at the Lady Hardinge Medical College in New Delhi, India. She then completed a residency in Internal Medicine at the University of Connecticut Health Center. Dr. Gupta then completed a fellowship in Hematology-Oncology at Georgetown University in Washington, D.C., and Thomas Jefferson University in Philadelphia, Pennsylvania. She subsequently completed a research fellowship in Genitourinary Oncology Translational Research at Thomas Jefferson University. Dr. Gupta also serves as the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee. She has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in numerous studies regarding bladder cancer. Dr. Gupta’s research has been published in peer-reviewed journals, including the Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, European Oncology, among others. She is the author of the American Urologic Association core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer. Dr. Gupta is active in several professional organizations, including the American Society of Clinical Oncology, American Urologic Association, American Association of Cancer Research, Society of Urologic Oncology, Society of Immunotherapy for Cancer, Bladder Cancer Advocacy Network, Prostate Cancer Foundation, and the European Society of Medical Oncology.

Share This

Chat with usLiveChat